There were a number of clinical studies to evaluate the effects of drug interventions on glycemic and glucose variability in the population of patients with T2DM by using CGM, such as dipeptidyl peptidase-4 inhibitors (DPP-4is), SGLT-2i, and GLP-1RA [35–38]. Here, DPP4 is linked to type 2 diabetes mellitus.